Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pitavastatin 2 mg once daily for reduction of major cardiovascular events in patients with clustered cardiovascular risk factors
KCT0000001Phase 3Recruiting
- Sponsor
- Korea Disease Control and Prevention Agency
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pitavastatin in hyperlipidemia, essential hypertension, diabetes mellitus (DM), sponsored by Korea Disease Control and Prevention Agency. Started May 2009; status: recruiting.
02
Drugs
pitavastatin
03
Conditions
hyperlipidemiaessential hypertensiondiabetes mellitus (DM)
Beyond the preview
Go deeper on KCT0000001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000001.